Suchergebnisse - "Locke, Frederick L"

PubPharm (199)

1

Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies

enthalten in: Expert review of anticancer therapy | 2024

von Oluwole, O. | Neelapu, S. | Ray, M. | +5

2

Applying the EHA/EBMT grading for ICAHT after CAR-T : comparative incidence and association with infections and mortality

enthalten in: Blood advances | 2024

von Rejeski, K. | Wang, Y. | Hansen, D. | +14

3

Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity

enthalten in: Blood | 2024

von Locke, F. | Siddiqi, T. | Jacobson, C. | +28

4

Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

enthalten in: Blood cancer journal | 2024

von Afrough, A. | Hashmi, H. | Hansen, D. | +27

5

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy

enthalten in: American journal of hematology | 2024

von Lunning, M. | Wang, H. | Hu, Z. | +20

6

Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma : outcomes by metabolic tumor volume

enthalten in: Blood | 2024

von Locke, F. | Oluwole, O. | Kuruvilla, J. | +12

7

Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

enthalten in: Transplantation and cellular therapy | 2024

von Akhtar, O. | Modi, K. | Kim, J. | +18

8

Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

enthalten in: Blood cancer discovery | 2024

von Faramand, R. | Lee, S. | Jain, M. | +30

9

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma : results from the US Lymphoma CAR-T Consortium

enthalten in: Blood advances | 2024

von Jain, M. | Jacobs, M. | Gao, F. | +23

CommentIn: Blood Adv. 2024 Feb 27;8(4):1051-1052. - PMID 38411993

10

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

enthalten in: Nature medicine | 2024

von Levine, B. | Pasquini, M. | Connolly, J. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[20]